Ionis Pharmaceuticals sank -4.9% this afternoon, compared to the S&P 500's day change of 2.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Ionis Pharmaceuticals has logged a 89.2% 52 week change, compared to 12.1% for the S&P 500
-
IONS has an average analyst rating of buy and is -15.85% away from its mean target price of $83.11 per share
-
Its trailing earnings per share (EPS) is $-1.61, which brings its trailing Price to Earnings (P/E) ratio to -43.4. The Health Care sector's average P/E ratio is 22.94
-
The company's forward earnings per share (EPS) is $-3.74 and its forward P/E ratio is -18.7
-
The company has a Price to Book (P/B) ratio of 18.24 in contrast to the Health Care sector's average P/B ratio is 3.19
-
The current ratio is currently 8.5, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $-546227000 and the average free cash flow growth rate is -17.2%
-
Ionis Pharmaceuticals's revenues have an average growth rate of -8.9% with operating expenses growing at -3.6%. The company's current operating margins stand at -67.4%
